



Argos Therapeutics
Investor Relations Department
4233 Technology Drive
Durham, NC 27704
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ARGS


Last Trade:	0.38
Trade Time:	4:00 PM ET Jun 26, 2017
Change:	-0.01 (-2.333%)
Day Range	0.37 - 0.41
52-Week Range	0.31 - 7.08
Volume	910,494

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 22, 2017

[Argos Therapeutics Announces Closing of \\$6.0 Million Secured Convertible Note Financing](#)

Jun 16, 2017

[Argos Therapeutics Announces \\$6,000,000 Secured Convertible Note Financing](#)

May 10, 2017

[Argos Provides Update on its ADAPT Trial Following Meeting with FDA](#)

Apr 18, 2017

[Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial](#)

Feb 22, 2017

[Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of Rocopuldencel-T in Metastatic Renal Cell Carcinoma for Futility Following Its Planned Interim Data Review](#)

Financials [\[View all \]](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Apr 29, 2016

[Proxy Statement \(DEF 14A\)](#)

May 10, 2017

[Quarterly Report \(10-Q\)](#)

Nov 14, 2016

[Quarterly Report \(10-Q\)](#)

Aug 15, 2016

[Quarterly Report \(10-Q\)](#)